



Universiteit
Leiden
The Netherlands

Cripto favors chondrocyte hypertrophy via TGF-beta SMAD1/5 signaling during development of osteoarthritis

Vinuesa, A.G. de; Sanchez Duffhues, G.; Blaney-Davidson, E.; Caam, A. van; Lodder, K.; Ramos, Y.; ... ; Dijke, P. ten

Citation

Vinuesa, A. G. de, Sanchez Duffhues, G., Blaney-Davidson, E., Caam, A. van, Lodder, K., Ramos, Y., ... Dijke, P. ten. (2021). Cripto favors chondrocyte hypertrophy via TGF-beta SMAD1/5 signaling during development of osteoarthritis. *The Journal Of Pathology*, 255(3), 330-342. doi:10.1002/path.5774

Version: Publisher's Version

License: [Creative Commons CC BY-NC-ND 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3212843>

Note: To cite this publication please use the final published version (if applicable).

Cripto favors chondrocyte hypertrophy via TGF- β SMAD1/5 signaling during development of osteoarthritis

Amaya Garcia de Vinuesa^{1†}, Gonzalo Sanchez-Duffhues^{2†*}, Esmeralda Blaney-Davidson³, Arjan van Caam³, Kirsten Lodder², Yolande Ramos⁴, Margreet Kloppenburg⁴, Ingrid Meulenbelt⁴, Peter van der Kraan³, Marie-José Goumans² and Peter ten Dijke^{1*}

¹ Department of Cell and Chemical Biology, Leiden University Medical Center, Oncode Institute, Leiden, The Netherlands

² Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands

³ Experimental Rheumatology & Advanced Therapeutics, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands

⁴ Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands

*Correspondence to: G Sanchez-Duffhues or P ten Dijke, Department of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands. E-mail: g.sanchez_duffhues@lumc.nl or p.ten_dijke@lumc.nl

†These authors contributed equally to this work.

Abstract

Chondrocytes in mice developing osteoarthritis (OA) exhibit an aberrant response to the secreted cytokine transforming growth factor (TGF)- β , consisting in a potentiation of intracellular signaling downstream of the transmembrane type I receptor kinase activin receptor-like kinase (ALK)1 against canonical TGF- β receptor ALK5-mediated signaling. Unfortunately, the underlying mechanisms remain elusive. In order to identify novel druggable targets for OA, we aimed to investigate novel molecules regulating the ALK1/ALK5 balance in OA chondrocytes. We performed gene expression analysis of TGF- β signaling modulators in joints from three different mouse models of OA and found an upregulated expression of the TGF- β co-receptor Cripto (*Tdgf1*), which was validated in murine and human cartilage OA samples at the protein level. *In vitro* and *ex vivo*, elevated expression of Cripto favors the hypertrophic differentiation of chondrocytes, eventually contributing to tissue calcification. Furthermore, we found that Cripto participates in a TGF- β –ALK1–Cripto receptor complex in the plasma membrane, thereby inducing catabolic SMAD1/5 signaling in chondrocytes. In conclusion, we demonstrate that Cripto is expressed in OA and plays a functional role promoting chondrocyte hypertrophy, thereby becoming a novel potential therapeutic target in OA, for which there is no efficient cure or validated biomarker.

© 2021 The Authors. *The Journal of Pathology* published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Keywords: TGF- β ; BMP; ALK; *Tdgf1*; cartilage; bone; calcification; joint; ageing

Received 20 January 2021; Revised 29 June 2021; Accepted 3 August 2021

No conflicts of interest were declared.

Introduction

Osteoarthritis (OA) is a painful and disabling condition of the joints affecting millions of people. Ageing is the primary risk factor, but how ageing results in OA remains an enigma. OA is characterized by degeneration of the articular cartilage, which has a very limited reparative capacity [1]. Therefore, detection of early tissue damage is essential to stop the progression of the disease. Unfortunately, existing diagnostic tools have low sensitivity and specificity and currently there is no validated cure for OA.

In healthy articular cartilage, chondrocytes maintain the fine balance between the production and degradation of the extracellular matrix (ECM). However, during OA, modifications in chondrocyte metabolism and environment (i.e. inflammation, hypoxia, or mechanical stress) disrupt this equilibrium. Chondrocytes then become

hypertrophic and increase the secretion of matrix metalloproteinases (MMPs), leading to degeneration, mineralization, and vascularization of the matrix. The underlying mechanism driving this phenomenon remains unclear.

The transforming growth factor beta (TGF- β) family of dimeric proteins plays crucial roles during cartilage and bone development and homeostasis [2–4]. TGF- β signaling is initiated upon interaction of soluble active TGF- β ligands with membrane receptors bearing intrinsic serine/threonine kinase activity. TGF- β binds to the constitutively active TGF- β type II receptor (T β RII), which subsequently associates with and *trans*-phosphorylates the TGF- β type I receptor (T β RI), also named activin receptor-like kinase 5 (ALK5). Upon ALK5 activation, a specific set of intracellular mediators named SMAD2/3 become phosphorylated, associate with SMAD4, and translocate into the nucleus to modulate gene expression [5]. Importantly, in chondrocytes [6] and other cell types,

such as endothelial cells [7], TGF- β can recruit the bone morphogenetic protein (BMP) receptor ALK1, thereby inducing SMAD1/5/8 activation. Induction of either SMAD2/3 or SMAD1/5/8 leads to different transcriptional responses, including the expression of genes related to ECM components or genes mediating osteogenic differentiation, respectively. Importantly, TGF- β signal transduction is fine-tuned by the so-called co-receptors, including Cripto [8], which modify the ligand–receptor affinity but lack an intracellular enzymatic motif to originate intracellular cascades upon activation [9]. Cripto (Cripto-1, teratocarcinoma-derived growth factor-1 or TDGF-1) is a small, glycosylphosphatidylinositol (GPI)-anchored protein that plays key roles during embryonic development, in part by regulating signal transduction initiated by the TGF- β family member Nodal [10]. In adult healthy tissue, its expression is very low or absent, but high levels are found in several human tumors [11,12]. Mechanistically, Cripto has been shown to act as an obligatory co-receptor for certain TGF- β ligands such as Nodal, leading to phosphorylation of SMAD2/3, while it can also inhibit SMAD2/3 phosphorylation induced by activin-A/B or TGF- β [10,13].

TGF- β is a central regulator of chondrocyte progenitor proliferation, differentiation, and ECM production, whereas its main activity is the prevention of hypertrophic differentiation [14,15]. Disruption of TGF- β signaling has been implicated in OA [16]. In ageing and OA cartilage, the ALK1/ALK5 ratio is increased, leading to preferential activation of the SMAD1/5 signaling pathway, which mediates the expression of matrix metalloproteinase (MMP)-13, thereby contributing to the degradation of the cartilage [6,17,18]. TGF- β signaling has been linked to other changes observed in the osteoarthritic joint (osteophyte formation, subchondral bone alterations, vascularization, and fibrosis) [19]. Ablation of endogenous TGF- β activity suppresses osteophyte formation *in vivo* but in contrast aggravates cartilage degeneration in OA-mouse models [20]. Therefore, selective interference with TGF- β receptor pathological signaling in the joint tissues may have therapeutic promise.

In this paper, we demonstrate that expression of the TGF- β co-receptor Cripto is increased during experimentally induced OA and in human osteoarthritic cartilage. Furthermore, we describe a novel function of Cripto forming a membrane receptor complex with TGF- β and enhancing the activation of SMAD1/5/8 and subsequent mineralization in chondrocytes. Our findings hold promise for the further development of novel therapies based on Cripto targeting, to treat this so far incurable disease.

Materials and methods

Ethics

Collection and handling of human tissues (RAAK study) were performed in accordance with the guidelines of the Medical and Ethics Committee in Leiden, The

Netherlands and the code of conduct of the Dutch Federation of Biomedical Scientific Societies (protocol No P08.239).

Animal procedures involving OA models were carried out after approval had been obtained from the Animal Ethics Committee of the Radboud University Nijmegen (DEC Nos RU-DEC 2010-036 and RU-DEC 2007-131). Isolation and studies involving embryonic mouse metatarsals were approved in protocol #14238, 16 December 2004 (Medical and Ethics Committee in Leiden, The Netherlands).

In vivo OA modeling

Three different *in vivo* experimental models were used in this study: ageing-induced OA, destabilization of the medial meniscus-induced OA, and STR/ort. In brief, C57BL/6N mice aged 6, 8, 12, 16 or 20 months ($n = 8–11$) and genetically predisposed STR/ort mice of ages 2, 4, 8, and 12 months ($n = 7$ or 8) were used to analyze the expression pattern of *Tdgf1* and related family members in relation to ageing. Histological examination of the knee joints was performed after dissection, fixation, decalcification in formic acid for 1 week, and then embedding in paraffin wax. Sections were cut at 5 μ m and stained with Safranin O and Fast Green, as described previously [21].

Histological evaluation was performed using a modified OARSI score [22]. In brief, medial and lateral tibiae and femora within one joint were stained as mentioned above and examined independently (five sections each). Grade (maximum score of the pathology) and stage (extent of the total damage) were scored and averaged per joint and cartilage surface, to obtain a mean grade and mean stage per joint and cartilage surface. Finally, the total OA score was calculated as the sum of the individual OA scores of each cartilage surface.

For surgical destabilization of the medial meniscus (DMM), C57BL/6N mice at 10–12 weeks of age were used to induce OA by transecting the anterior attachment of the medial meniscus to the tibia of a right knee joint, as previously described [16]. Following the DMM operation, mice were sacrificed at different time points (2, 4 or 6 weeks) after surgery, including at least three up to 11 mice at each time point. Knee joints of sacrificed mice were isolated for histology and compared with those from control mice ($n = 3$). OA was confirmed by histological evaluation as described previously [23]. The corresponding left knee joint of each mouse was used as a control for comparison of DMM-operated versus non-operated knee joints.

Gene target identification

To obtain RNA samples, the cartilage dissected from the joint was instantly frozen in liquid nitrogen and crushed using a dismembrator. The crushed material was dissolved in RLT buffer supplied with the RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). Samples were treated with proteinase K, and subsequently RNA was

isolated further using the RNeasy Mini Kit according to the manufacturer's protocol. Since the RNA yield obtained from mouse cartilage is extremely low, we used the WT-Ovation RNA Amplification System (NuGEN, Bembel, The Netherlands) with 50 ng of total RNA, for which RNA from different animals needed to be pooled together. The amplified RNA was subsequently loaded in a custom-made PCR Array (RT² Profiler PCR array, SAB Biosciences, Qiagen) following the instructions provided by the supplier.

Cell culture and reagents

ATDC5 cells (Riken Cell Bank, Saitama, Japan) were cultured in DMEM/F12 medium supplemented with 5% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin in a humidified incubator with 95% air and 5% CO₂ at 37 °C. Immortalized C28/I2 human chondrocytes [17], HEK293T cells, and C₂C₁₂ (ATCC, Rockville, MD, USA) murine myoblast cells were maintained in DMEM medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), and penicillin/streptomycin (Invitrogen). TGF-β3 was a kind gift from Dr A Hinck (University of Pittsburgh, PA, USA). Recombinant BMP9 and Cripto were purchased from R&D Systems (Minneapolis, MN, USA) and Cell Signaling Technology (Leiden, The Netherlands), respectively. Anti-human ALK1 (investigational drug anti-hALK1, PF-03446962; Pfizer, New York, NY, USA) has been described previously [24] and was used at a final concentration of 1 µg/ml.

In vitro mineralization assays

We used three different *in vitro* models of chondrogenic mineralization. For the first model, 5×10^4 ATDC5 or C28/I2 cells were seeded in 48-well plates to form a monolayer and were subsequently incubated for 21 days in mineralization medium (DMEM/F12) containing insulin–transferrin–selenium (ITS; Gibco), 0.2 mM ascorbic acid (Sigma-Aldrich/Merck, Darmstadt, Germany), and 10 mM β-glycerophosphate (Sigma-Aldrich). Alternatively, ATDC5 cells were incubated for 21 days in differentiation medium containing ITS and 0.2 mM ascorbic acid, and then switched to mineralization medium including 10 mM β-glycerophosphate for 4 days. For 3D chondrogenic micromass assays, stably transduced ATDC5 cells were trypsinized and washed once with PBS. 3×10^5 cells were counted per micromass and resuspended in 10 µl of culture medium. Very carefully, 10 µl drops were deposited in the center of wells in a 24-well plate and placed in an incubator for 2 h. Next, 500 µl of DMEM-F12 5% FBS containing 1x ITS (Gibco) was carefully added to each well. After 24 h, the medium was replaced by DMEM-F12 5% FBS containing 1x ITS, supplemented with 0.2 mM ascorbic acid and 10 mM β-glycerophosphate and TGF-β (10 ng/ml), for the time indicated. In all differentiation experiments, the medium was refreshed every 4 days. Afterwards, cells were washed twice with PBS and fixed with 3.7%

formaldehyde for 5 min. Fixed cells were washed twice with distilled water and measurement of calcium deposition was performed using Alizarin Red staining (ARS), as described previously [25]. Precipitates that originated from three independent ARS assays were dissolved using 10% cetylpyridinium chloride and absorbance was measured at 570 nm. Representative images were acquired using a Leica DM IL LED microscope (Leica Biosystems, Amsterdam, The Netherlands) loaded with a 10× magnification objective and coupled to a digital camera.

Fetal mouse bone explants (metatarsals assay)

Fetal wild-type C57BL/6N or conditional *Tdgfl* knockout (*Tdgfl*^{tm2.2Mms}) mouse embryos at 15.5–17.5 days post-implantation (dpi) were used for this experiment. The middle three metatarsals from the embryonic hind limbs were dissected under sterile conditions and cultured independently in 48-well plates containing 200 µl of αMEM supplemented with 10% FBS, 0.05 mg/ml ascorbic acid, L-glutamine, 0.05 mg/ml gentamycin, 0.25 mg/ml amphotericin B, 1 mM β-glycerophosphate, and 0.2% bovine serum albumin (BSA) Cohn fraction V, as described previously [26,27]. In addition, the osteogenic medium described above was supplemented with recombinant factors (TGF-β₃, 10 ng/ml; Cripto, 200 ng/ml) and incubated for 6 days. For experiments analyzing the effect of genetic deletion of Cripto (*Tdgfl*), increasing volumes of supernatant containing control viruses or Cre-expressing lentiviruses were added to the metatarsal cultures at day 0 and cultured for 4 days, prior to stimulation as described above. During culture, lengths of hypertrophic, mineralized, and proliferative cartilage were measured under an inverted microscope. In these embryonic rudiments, the first zone of hypertrophic cartilage is visible as a clear area in the center, as demonstrated previously [28]. The mineralized cartilage is the dark area that develops in the center of the hypertrophic zone, and the proliferative zone is the cartilage at the ends of the embryonic rudiment.

Statistical analyses

Student's *t*-test was used for statistical analysis, with $p < 0.05$ considered as statistically significant. All experiments were performed at least in triplicate, unless otherwise indicated.

Technical details for Immunohistochemical staining, immunofluorescence, and Mankin scoring; RT-qPCR; Western blotting; Iodination and ligand affinity labeling of cell surface receptors; and Lentivirus production are provided in Supplementary materials and methods.

Results

The expression of the TGF-β co-receptor Cripto is increased prior to osteoarthritis development

In order to find novel druggable targets to revert pathological TGF-β signaling in OA, we analyzed secreted

TGF- β signaling modulators that are not essential for signaling but can fine-tune TGF- β signaling in a cell and/or tissue-type and dynamic manner. Since human

cartilage tissues can be obtained only at the end stage of the disease, articular cartilage from C57Bl/6N mice that spontaneously develop OA during ageing was




Figure 1 Legend on next page.

analyzed over a period of 20 months. Of note, we found that the mRNA levels of *Tdgfl*, encoding the TGF- β co-receptor Cripto, were strikingly increased towards the onset of OA (Figure 1A), which was confirmed at the protein level in joints of 8-month-old mice (Figure 1B). Interestingly, other soluble factors related to the activity of Cripto (i.e. *Nodal*, *Lefty1*, *Lefty2*, *Cer1*) were also induced at early stages, suggesting a common underlying mechanism. In order to correlate the expression of Cripto with OA onset and development, joints from ageing C57BL/6N mice were scored following a modified OARSI method [22]. Importantly, *Tdgfl* expression was found to be induced prior to the appearance of early histopathological signs of OA in the joints of ageing mice, which become significant at 12 months (Figure 1C and supplementary material, Figure S1A), coinciding with an induction in the expression of the chondrogenic markers aggrecan (*Acan*), collagen type X alpha 1 chain (*Col10a1*), collagen type II alpha 1 chain (*Col2a1*), and matrix metalloproteinase 13 (*Mmp13*) (Figure 1D). To further validate the expression of *Tdgfl* during OA, we monitored the expression of this transcript in additional murine models of spontaneously accelerated STR/ort and induced (DMM) OA. In the well-characterized genetic STR/ort model [29], we found an initial early induction in 4-month-old STR/ort mice, followed by a progressive downregulation of *Tdgfl* (Figure 1E), similar to the expression pattern of a number of chondrogenic differentiation markers (Figure 1F), thus preceding the development of severe OA histopathology (supplementary material, Figure S1B). In a mouse model of induced OA consisting in the mechanical destabilization of the medial meniscus (DMM), *Tdgfl* expression was progressively reduced after 4 and 6 weeks, coinciding with a downregulation in chondrogenic genes (supplementary material, Figure S2A,B). Finally, in order to validate these observations in human OA lesions, we scored the expression of Cripto in a small subset of articular cartilage biopsies collected from OA patients following stratification by Mankin score [30–32] (supplementary material, Figure S3A). As shown in Figure 1G, Cripto was expressed in chondrocyte-like cells expressing the hypertrophic marker COL10A1 present in the superficial and deeper layers of the articular cartilage, and its expression was enhanced in severely damaged joints of

OA donors (Figure 1H and supplementary material, Figure S3B). These results confirm the expression of the TGF- β co-receptor Cripto in human cartilage and relate it to the development of OA.

Cripto mediates chondrogenic hypertrophy *in vitro*

We aimed next to investigate the functional role of Cripto in OA. Therefore, we made use of different protocols to achieve chondrocyte hypertrophy and calcification *in vitro*. First, we cultured ATDC5 mouse prechondrocytes as monolayers for 21 days in the presence of insulin–transferrin–selenium (ITS), ascorbate, and β -glycerophosphate (Figure 2A). In this model, the cells were stained positively for calcium deposits using Alizarin Red (AR) from day 14 onwards (Figure 2B). This staining correlated with a significant increase in the expression of the chondrogenic markers *Col10a1*, *Col2a1*, and alkaline phosphatase (*Alp*). Importantly, Cripto expression was elevated towards late differentiation stages (Figure 2C and supplementary material, Figure S4). A shift in the use of the TGF- β type I receptors ALK5 (encoded by *Tgfb1*) and ALK1 (*Acrv1l*) has been shown during the progression of OA [6]. In this *in vitro* model, we observed a trend towards upregulation of both genes during the progression of differentiation. Since we detected Cripto expression at later stages of chondrocyte differentiation, we developed a two-step differentiation protocol to study the correlation between Cripto expression and cell calcification. ATDC5 cells were exposed to ITS for 21 days and thereafter supplemented (or not) with ascorbate and β -glycerophosphate until day 25 (Figure 2D) to induce cell calcification. Using this protocol, *Tdgfl* mRNA and protein expression was highly induced from day 25 onwards in response to supplementation of the medium with ascorbate and β -glycerophosphate (Figure 2E,F and supplementary material, Figure S4), therefore suggesting a correlation of Cripto with chondrocyte hypertrophy and cartilage ossification. Finally, we validated our findings in a 3D model of chondrocyte hypertrophy, consisting in 3D micromass cultures of highly condensed ATDC5 cells, as reported elsewhere [33]. To study the role of Cripto in hypertrophy, we first stably knocked down *Tdgfl* using two different short hairpin RNA (shRNA) constructs (Figure 2G). Notably, genetic

Figure 1. Cripto expression correlates with OA development. (A) Gene expression analysis during age-induced osteoarthritis in C57BL/6N mice. RNA was isolated from cartilage of C57BL/6 mice at different ages (6, 8, 12, 16, and 20 months). Relative mRNA expression of *Tdgfl* (encoding Cripto), *Nodal*, *Lefty1*, *Lefty2*, and *Cerberus* (*Cer1*) compared with 6 months old is shown. RNA was pooled from 8–11 mice per group. (B) Immunohistochemical analysis of Cripto expression in paraffin sections from 8-month-old C57BL/6N mouse joints (objective 10 \times and 40 \times in zoomed image). (C) Total histopathological modified OARSI score of C57BL/6N mouse joints during the period 6–20 months old. (D) mRNA expression analysis of the chondrogenic genes collagen type X alpha 1 chain (*Col10a1*), matrix metalloproteinase 13 (*Mmp13*), collagen type II alpha 1 chain (*Col2a1*), and aggrecan (*Acan*) in samples from A. (E) Gene expression analysis in femur samples from spontaneously developed OA STR/ort mice at different ages (2, 4, 6, and 8 months). Expression levels are related to 2-month-old samples (7 or 8 individual animals pooled per group). (F) mRNA expression analysis of the chondrogenic genes collagen type X alpha 1 chain (*Col10a1*), matrix metalloproteinase 13 (*Mmp13*), collagen type II alpha 1 chain (*Col2a1*), and aggrecan (*Acan*) in femur samples isolated from STR/ort mice at different ages (2, 4, 6, and 8 months). (G) Immunohistochemical analysis of Cripto expression in formalin-fixed, paraffin-embedded (FFPE) sections from OA patients. Superficial and deeper layers of cartilage samples are shown, comparing different degrees of damage within the same section. Representative sections are shown (objective 10 \times and 20 \times for zoomed images). (H) Correlation of Cripto expression and Mankin score (for OA staging) in human OA samples. * p < 0.05; *** p < 0.0001.




Figure 2. Cripto expression analysis during chondrogenic differentiation *in vitro*. (A) Schematic overview of the experimental design (one-step protocol). ATDC5 cells were cultured in the presence of chondrogenic differentiation medium containing insulin–transferrin–selenium (ITS), ascorbic acid (Asc), and β -glycerolphosphate (β GP) for 21 days. At 0, 7, 14, and 21 days, the medium was refreshed. (B) Alizarin Red staining (ARS) to visualize calcium deposits was performed on ATDC5 cells cultured in monolayer under chondrogenic differentiation conditions at days 0, 7, 14, and 21 (objective magnification 10 \times). (C) Relative mRNA expression corresponding to *Tdgf1* (encoding Cripto), *Acvrl1* (encoding ALK1), *Tgfb1* (encoding ALK5), collagen type X alpha 1 chain (*Col10a1*), collagen type II alpha 1 chain (*Col2a1*), and alkaline phosphatase (*Alp*) in ATDC5 cells at 0, 7, 14, and 21 days of culture under chondrogenic conditions (one-step model). (D) Schematic overview of the experimental design (two-step protocol). ATDC5 cells were cultured in the presence of chondrogenic differentiation medium containing ITS for 21 days. From day 21, Asc and β GP were added to the medium. At 0, 7, 14, 21, and 25 days, the medium was refreshed. (E) ARS was performed on ATDC5 cells cultured in monolayer under chondrogenic differentiation conditions (two-step protocol) at days 0, 3, 14, 21, and 25 (or 25 days with Asc and β GP, 25+) (objective magnification 10 \times). (F) Relative mRNA expression of *Tdgf1*, *Acvrl1*, *Tgfb1*, *Col10a1*, *Col2a1*, and *Alp* in ATDC5 cells at 3, 14, and 25 days (with or without Asc and β GP, 25+) of culture under chondrogenic conditions (two-step protocol). (G) ARS performed in 3D chondrogenic pellets of ATDC5 stably knocked down for *Tdgf1*. Two control lines and two *Tdgf1* shRNAs are shown. Relative expression of *Tdgf1* and quantification of ARS upon solubilization are shown. (H) ARS performed in 3D chondrogenic pellets of ATDC5 stably overexpressing *Tdgf1*. Two control lines and one overexpression (OE) line are shown. Relative expression of *Tdgf1* and quantification of ARS upon solubilization are shown. * p < 0.05; ** p < 0.001; *** p < 0.0001.

depletion of *Tdgfl* effectively inhibited the deposition of calcified matrix by condensed chondrocytes. Moreover, stable overexpression of *Tdgfl* significantly augmented the calcification of 3D chondrocyte micropellets, as assessed by AR staining (Figure 2H). Our results suggest that increased expression of Cripto in hypertrophic chondrocytes favors calcification.

Cripto modulates chondrocyte hypertrophy *ex vivo*

In order to functionally verify a physiological role for Cripto in mediating chondrocyte hypertrophy, we made use of an *ex vivo* metatarsals culture system. In this model, mouse embryonic (E15.5–17.5) bone metatarsals are resected and cultured in osteogenic medium, subsequently expanding *ex vivo* in a process that resembles endochondral ossification and chondrocyte differentiation [26,27]. After culture in osteogenic medium, the length of the dark mineralized area is measured and related to the total bone length. Using this model, we first investigated the effect of recombinant Cripto in chondrocyte hypertrophy. Of note, after 7 days of culture, all metatarsals from the control group had grown in length and showed an enlarged dark area in the center, corresponding to the hypertrophic area. Ectopic addition of TGF- β effectively suppressed expansion of the hypertrophic area (Figure 3A,B). Furthermore, pre-incubation with recombinant Cripto rescued the inhibitory effect of TGF- β , suggesting that Cripto could counteract the effect of TGF- β during chondrocyte differentiation and hypertrophy, and possibly during the development of OA. To further investigate the role of Cripto during chondrocyte hypertrophy, we used middle metatarsals isolated at E17.5 from conditional *Tdgfl* knockout embryos (*Tdgfl*^{tm2.2Mms}). As assessed by immunofluorescence labeling of Cripto and the hypertrophic chondrocyte marker COL10A1, double-positive cells expressing Cripto and COL10A1 were found to be accumulated at the boundaries of the hypertrophic area (Figure 3C). Next, we genetically deleted Cripto using increasing concentrations of lentivirus encoding the Cre recombinase (or a control virus) and cultured these mouse metatarsals in osteogenic medium for 10 days. Immunofluorescence analysis showed that Cripto was efficiently downregulated in a dose-dependent manner following lentiviral infection (Figure 3C). Moreover, the genetic deletion of Cripto significantly reduced the expression of COL10A1, as well as the length of the mineralized area, compared with control infected metatarsals (Figure 3D,E). We obtained similar results by interfering with Cripto expression at an earlier embryonic stage using metatarsals isolated at E15.5 (supplementary material, Figure S5). Our results demonstrate a functional role for Cripto tuning the hypertrophic response of chondrocytes to TGF- β signaling.

Cripto fine-tunes TGF- β signaling by enhancing SMAD1/5 activation

Finally, we investigated the molecular mechanisms by which Cripto modulates cellular responses to TGF- β in

chondrocytes. A mechanism proposed to mediate OA development involves a shift in intracellular signaling induced by TGF- β , from the activation of intracellular SMAD2/3 via the ALK5 receptor, towards the phosphorylation of SMAD1/5 via ALK1 [6]. However, the mechanisms underlying this shift remain elusive. Given that Cripto can modulate TGF- β signaling in other cell types [34–36], we hypothesized that Cripto may modulate the balance between TGF- β and BMP signaling through ALK1/ALK5 in OA chondrocytes. First, we investigated the effect of Cripto on TGF- β -induced signaling in ATDC5 chondrocytic cells. Pre-incubation with increasing concentrations of recombinant Cripto led to enhanced phosphorylation of SMAD1/5 upon TGF- β stimulation in a dose-dependent manner (Figure 4A). We confirmed the effect of Cripto on phospho-SMAD1 by immunofluorescence (Figure 4B). Moreover, we analyzed the expression of phospho-SMAD1 and phospho-SMAD2 in mouse metatarsals genetically depleted for Cripto. As shown in supplementary material, Figures S6 and S7, addition of Cre lentiviruses led to a marked inhibition of Cripto expression. Interestingly, we observed an overall decrease in phospho-SMAD1-stained cells in the absence of Cripto (supplementary material, Figure S6), whereas phospho-SMAD2-stained cells were augmented (supplementary material, Figure S7), in line with previous reports describing an inhibitory effect of Cripto on TGF- β signaling [36,37].

Given that TGF- β -induced SMAD1/5 activation is mediated by ALK1, which also transduces signaling induced by BMP9 [38,39], we studied the effect of Cripto on BMP9 signaling. As shown in Figure 4C, pre-incubation with recombinant Cripto also enhanced BMP9-induced SMAD1/5 phosphorylation, suggesting a functional interaction between ALK1 and Cripto. We then hypothesized that Cripto facilitates a physical interaction between TGF- β and ALK1. To demonstrate this, we performed ligand–receptor binding affinity assays using radiolabeled TGF- β . HEK293T cells overexpressing T β RII-myc and either ALK1-HA or ALK5-HA were incubated with radioactive TGF- β in the presence of recombinant Cripto. Of note, we detected TGF- β receptor complexes containing either ALK1 or ALK5 in the absence of recombinant Cripto, whereas pre-incubation with Cripto enhanced the association of TGF- β with a membrane complex containing T β RII, ALK1, and Cripto (Figure 4D,E). Our results indicate that Cripto preferentially interacts with ALK1 in receptor complexes at the membrane, thereby favoring SMAD1/5 phosphorylation in response to either TGF- β or BMP9. To functionally validate our hypothesis, we made use of a human-specific ALK1 neutralizing antibody (anti-hALK1) [24] as a drug candidate to fine-tune TGF- β signaling through ALK1 in chondrocytes. As shown in supplementary material, Figure S8, incubation of human C28/I2 chondrogenic cells with anti-hALK1 led to a significant decrease in cell mineralization in C28/I2 cells overexpressing Cripto, as measured by ARS (supplementary material, Figure S8A). These data were in line with inhibition of the expression of the




Figure 3. Cripto enhances chondrocyte hypertrophy ex vivo. (A) E17.5 metatarsals incubated for 7 days with osteogenic medium, recombinant Cripto (200 ng/ml), and/or TGF- β (10 ng/ml). The hypertrophic/calcified area is visualized as the central dark area. A representative picture is shown (objective 4 \times). (B) Statistical analysis of the hypertrophic area/total length calculated for all conditions shown in A ($n = 7$). (C) Immunofluorescence labeling for Cripto (red channel), collagen type X alpha 1 chain (COL10A1, green channel), and cell nuclei (DAPI, blue channel) in E17.5 *Tdgfr1^{tm2.2Mms}* metatarsals incubated for 10 days in osteogenic medium with control- or Cre-lentivirus particles. (D) Representative bright-field images of E17.5 *Tdgfr1^{tm2.2Mms}* metatarsals incubated for 10 days with control lentiviruses or increasing concentration of lentivirus particles encoding the Cre recombinase. Objective 4 \times . (E) Quantification analyses for the experimental conditions depicted in D ($n = 12$). * $p < 0.05$; ** $p < 0.001$; *** $p < 0.0001$.




Figure 4 Legend on next page.

chondrogenic markers *MMP13*, *COL10A1*, and *COL2A1* (supplementary material, Figure S8B). Taken together, these data show that this mechanism, which may be shared by other cell types, mediates the shift in TGF- β signaling previously described to alter chondrocyte homeostasis, eventually contributing to OA development.

Discussion

Osteoarthritis (OA) is a painful and disabling condition of the joints affecting millions of people, for which there is no validated cure or a useful biomarker, despite the extensive search for druggable targets to modulate the response of chondrocytes within the affected joints. It has been shown that TGF- β signaling plays a key role in chondrocyte differentiation and activation, and disruption of the TGF- β pathway has been associated with OA. Particularly, in osteoarthritic chondrocytes, TGF- β ligands progressively shift from canonical ALK5 signaling (thus inducing SMAD2/3 activation and subsequent anabolic signaling) towards a membrane complex containing ALK1 (leading to SMAD1 activation and catabolic responses). Unfortunately, the mechanistic details underlying this pathological shift have not yet been identified.

To the best of our knowledge, this report is the first demonstration of a functional role of the TGF- β family co-receptor Cripto in cartilage homeostasis. We first showed increased expression of *Tdgfl* (encoding Cripto) in three different animal models of OA and in tissue sections from OA donors. We found a correlation between Cripto expression and disease severity, specifically in articular chondrocytes. Interestingly, Cripto (*Tdgfl*) was not detected in our previous microarray analysis, or in our RNA sequencing analysis of 35 paired samples of OA-affected cartilage [31]. To determine whether the different cohorts studied or discrepancies between mRNA and protein expression levels may underlie our different observations will require further studies.

Next, we used different *in vitro* models of chondrocyte hypertrophy and differentiation to demonstrate that Cripto is expressed in terminally differentiated (hypertrophic) chondrocytes and its inhibition partially prevents cell calcification. Mechanistically, we have shown that Cripto promotes TGF- β signaling via ALK1–phospho SMAD1 by physically taking part in a receptor complex involving TGF- β , ALK1, and T β R2, and also augments BMP9-induced SMAD1/5 activation

(Figure 5). Finally, we validated our findings using gain and loss of Cripto in an *ex vivo* model of endochondral ossification, where Cripto modulates the differentiation of growth plate chondrocytes. Taken together, our results highlight the potential of Cripto as a therapeutic target and biomarker for OA.

Cripto has been shown previously to bind to T β R2, thereby compromising TGF- β signaling via ALK5 [36]. In chondrocytes *in vitro*, we observed a minor effect on SMAD2 phosphorylation, in comparison with the stimulatory effect on SMAD1/5. Moreover, Cripto also enhanced BMP9-induced activation of SMAD1/5, thus supporting the effect via ALK1. Therefore, it is possible that the function of Cripto is determined by the relative expression of certain BMP and TGF- β membrane receptors, which differ in different cell types. Our studies are consistent with a role for Cripto in stimulating chondrocyte hypertrophy via enhanced SMAD1/5 activation in response to both TGF- β and BMP9. The increased expression of Cripto combined with the previously documented shift in the ALK1/ALK5 ratio suggests that Cripto exacerbates the impact of this shift toward BMP signaling. Our studies demonstrating the existence of Cripto complexes with ALK1 suggest that this effect is direct. A shift in the TGF- β ALK1/ALK5 ratio has been previously described in endothelial cells (ECs), where activation of ALK5 inhibits EC proliferation and migration, whereas ALK1 induction results in increased migration and proliferation [40]. Whether Cripto may favor ALK1 signaling in ECs remains to be studied. Interestingly, we have recently determined that circulating ECs from patients with a very rare disease named fibrodysplasia ossificans progressiva (FOP) express higher levels of Cripto [25]. FOP is due to enhanced SMAD1/5 signaling and subsequent heterotopic ossification linked to congenital mutations in the TGF- β family receptor ACVR1 (ALK2) [41]. Furthermore, Cripto may act in an autocrine/paracrine manner, as Cripto can be shed from the cell membrane in response to different stimuli [42,43]. Therefore, in our metatarsal assays, even though we observe a main effect in double-positive COL10A1/Cripto cells (likely chondrocytes), we cannot exclude that soluble Cripto may influence the surrounding cells too (for example, osteoblast progenitors), thereby modulating tissue calcification. Moreover, chondrocytes may not be the only source of Cripto in the OA joint. As such, macrophages [35], hematopoietic stem cells [44], and muscle satellite cells [34], at least, express Cripto in musculoskeletal tissues. Further research may be required to understand

Figure 4. Cripto modulates TGF- β –Smad1/5 signaling. (A) Western blotting analysis of ATDC5 cells serum-starved and pre-incubated for 30 min with recombinant Cripto and stimulated with TGF- β for 45 min. Quantification normalized to GAPDH. (B) Immunofluorescence analysis for pSMAD1 in ATDC5 cells serum-starved and pre-incubated with Cripto (200 ng/ml) and stimulated with TGF- β (5 ng/ml) for 45 min. (C) Western blotting was performed for ATDC5 cells stimulated with either TGF- β (5 ng/ml) or BMP9 (1 ng/ml) upon pre-incubation with Cripto (200 ng/ml) for 30 min. Quantification normalized to vinculin. (D) Radioactive TGF- β ligand binding affinity assay performed in HEK293T cells overexpressing combinations of overexpressed ALK1-HA, ALK5-HA, and T β R2-myc, and pre-incubated with soluble Cripto (200 ng/ml). Immunoprecipitation was performed for T β R2, ALK1, and ALK5. (E) Quantification by densitometry analysis of the indicated TGF- β receptors bound to radiolabeled TGF- β .




Figure 5. Cripto is expressed in osteoarthritic chondrocytes to modulate TGF- β signaling. Osteoarthritis (OA) is a painful and disabling age-related condition of the joints caused by progressive degeneration of the articular cartilage. Previous reports have shown that the cytokine transforming growth factor (TGF)- β plays an essential role in cartilage homeostasis via induction of intracellular signal transduction initiated by the TGF- β type I receptor ALK5, inducing anabolic functions. Hereby, we report a novel function of the TGF- β co-receptor Cripto (*Tdgf1*) in OA. Cripto is expressed in chondrocytes during OA, where it interacts with TGF- β receptors on the chondrocyte plasma membrane, thereby favoring the formation of TGF- β -ALK1 receptor complexes. Unlike ALK5, ALK1 downstream signaling induces chondrocyte hypertrophy and mineralization, eventually contributing to the development of OA. Therefore, our results shine light on the mechanisms underlying OA and highlight Cripto as a novel druggable target for this incurable disease.

whether membrane-bound and soluble Cripto may have differential effects depending on the cell type and milieu of TGF- β ligands to which the cells are exposed.

In summary, our studies provide biochemical and genetic evidence that Cripto is a central mediator of OA progression and chondrocyte hypertrophy via modulation of BMP/TGF- β signaling. Further research may explore the potential of Cripto in normal cartilage development and maintenance, as a biomarker for OA in serum or synovial fluid of patients, and as a target for the development of specific antagonists to prevent chondrocyte hypertrophy.

Acknowledgements

Our research is supported by the Cancer Genomics Centre Netherlands and the PHAEDRA-IMPACT consortium (CGC.NL to PtD and PHAEDRA-IMPACT to PtD and MJG). AGV was supported by the Dutch Arthritis Association (Reumafonds). GSD is sponsored by AFM-Telethon (#22379), FOP Italia, Fundació La Marató de TV3 (#202038), and the RECONNECT consortium (belonging to the Netherlands Cardiovascular Research Initiative, the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the

Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences). We thank Dr Peter C Gray (Salk Institute for Biological Studies, La Jolla, CA, USA) for providing the Cripto plasmids and the Cripto antibody. We would like to acknowledge Dr Karen Lyons for critical reading of and constructive advice on our manuscript, and C van Munsteren and G van der Zon for excellent technical assistance.

Author contributions statement

AGV, GSD, EBD, AVC and YR designed and performed experiments and analyzed and visualized the data. KL performed experiments and analyzed and visualized the data. GSD, MJG and PtD wrote the manuscript. YR, MG and IM provided human samples. MJG, PVK and PtD supervised the study. GSD, MJG and PtD acquired funding.

References

1. Wieland HA, Michaelis M, Kirschbaum BJ, et al. Osteoarthritis – an untreatable disease? *Nat Rev Drug Discov* 2005; **4**: 331–344.

2. Salazar VS, Gamer LW, Rosen V. BMP signalling in skeletal development, disease and repair. *Nat Rev Endocrinol* 2016; **12**: 203–221.
3. Pogue R, Lyons K. BMP signaling in the cartilage growth plate. *Curr Top Dev Biol* 2006; **76**: 1–48.
4. Janssens K, ten Dijke P, Janssens S, *et al*. Transforming growth factor- β 1 to the bone. *Endocr Rev* 2005; **26**: 743–774.
5. Hill CS. Transcriptional control by the SMADs. *Cold Spring Harb Perspect Biol* 2016; **8**: a022079.
6. Blaney Davidson EN, Remst DF, Vitters EL, *et al*. Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice. *J Immunol* 2009; **182**: 7937–7945.
7. Goumans MJ, Valdimarsdottir G, Itoh S, *et al*. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGF β /ALK5 signaling. *Mol Cell* 2003; **12**: 817–828.
8. Nagaoka T, Karasawa H, Castro NP, *et al*. An evolving web of signaling networks regulated by Cripto-1. *Growth Factors* 2012; **30**: 13–21.
9. Heldin CH, Moustakas A. Signaling receptors for TGF- β family members. *Cold Spring Harb Perspect Biol* 2016; **8**: a022053.
10. Yeo C, Whitman M. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. *Mol Cell* 2001; **7**: 949–957.
11. Watanabe K, Meyer MJ, Strizzi L, *et al*. Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. *Stem Cells* 2010; **28**: 1303–1314.
12. Bianco C, Strizzi L, Mancino M, *et al*. Identification of Cripto-1 as a novel serologic marker for breast and colon cancer. *Clin Cancer Res* 2006; **12**: 5158–5164.
13. Aykul S, Parenti A, Chu KY, *et al*. Biochemical and cellular analysis reveals ligand binding specificities, a molecular basis for ligand recognition and membrane association-dependent activities of Cripto-1 and Cryptic. *J Biol Chem* 2017; **292**: 4138–4151.
14. van der Kraan PM, Blaney Davidson EN, Blom A, *et al*. TGF- β signaling in chondrocyte terminal differentiation and osteoarthritis: modulation and integration of signaling pathways through receptor-Smads. *Osteoarthritis Cartilage* 2009; **17**: 1539–1545.
15. Madej W, van Caam A, Blaney Davidson E, *et al*. Unloading results in rapid loss of TGF β signaling in articular cartilage: role of loading-induced TGF β signaling in maintenance of articular chondrocyte phenotype? *Osteoarthritis Cartilage* 2016; **24**: 1807–1815.
16. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. *Osteoarthritis Cartilage* 2007; **15**: 1061–1069.
17. Finnson KW, Parker WL, ten Dijke P, *et al*. ALK1 opposes ALK5/Smad3 signaling and expression of extracellular matrix components in human chondrocytes. *J Bone Miner Res* 2008; **23**: 896–906.
18. van der Kraan PM, Goumans MJ, Blaney Davidson E, *et al*. Age-dependent alteration of TGF- β signalling in osteoarthritis. *Cell Tissue Res* 2012; **347**: 257–265.
19. Zhen G, Wen C, Jia X, *et al*. Inhibition of TGF- β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. *Nat Med* 2013; **19**: 704–712.
20. van Beuningen HM, van der Kraan PM, Arntz OJ, *et al*. Transforming growth factor- β 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. *Lab Invest* 1994; **71**: 279–290.
21. Blaney Davidson EN, Scharstuhl A, Vitters EL, *et al*. Reduced transforming growth factor- β signaling in cartilage of old mice: role in impaired repair capacity. *Arthritis Res Ther* 2005; **7**: R1338–R1347.
22. Waldstein W, Perino G, Gilbert SL, *et al*. OARSI osteoarthritis cartilage histopathology assessment system: a biomechanical evaluation in the human knee. *J Orthop Res* 2016; **34**: 135–140.
23. Pritzker KP, Gay S, Jimenez SA, *et al*. Osteoarthritis cartilage histopathology: grading and staging. *Osteoarthritis Cartilage* 2006; **14**: 13–29.
24. van Meeteren LA, Thorikay M, Bergqvist S, *et al*. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. *J Biol Chem* 2012; **287**: 18551–18561.
25. Sánchez-Duffhues G, Williams E, Benderitter P, *et al*. Development of macrocycle kinase inhibitors for ALK2 using fibrodysplasia ossificans progressiva-derived endothelial cells. *JBMR Plus* 2019; **3**: e10230.
26. Haaijman A, Karperien M, Lanske B, *et al*. Inhibition of terminal chondrocyte differentiation by bone morphogenetic protein 7 (OP-1) *in vitro* depends on the periarticular region but is independent of parathyroid hormone-related peptide. *Bone* 1999; **25**: 397–404.
27. Deckers MM, Smits P, Karperien M, *et al*. Recombinant human extracellular matrix protein 1 inhibits alkaline phosphatase activity and mineralization of mouse embryonic metatarsals *in vitro*. *Bone* 2001; **28**: 14–20.
28. Haaijman A, D'Souza RN, Bronckers AL, *et al*. OP-1 (BMP-7) affects mRNA expression of type I, II, X collagen, and matrix Gla protein in ossifying long bones *in vitro*. *J Bone Miner Res* 1997; **12**: 1815–1823.
29. Blaney Davidson EN, Vitters EL, van der Kraan PM, *et al*. Expression of transforming growth factor- β (TGF β) and the TGF β signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation. *Ann Rheum Dis* 2006; **65**: 1414–1421.
30. Mankin HJ, Dorfman H, Lippiello L, *et al*. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. II. Correlation of morphology with biochemical and metabolic data. *J Bone Joint Surg Am* 1971; **53**: 523–537.
31. Ramos YF, den Hollander W, Bovée JV, *et al*. Genes involved in the osteoarthritis process identified through genome wide expression analysis in articular cartilage; the RAAK study. *PLoS One* 2014; **9**: e103056.
32. Bos SD, Bovée JV, Duijnisveld BJ, *et al*. Increased type II deiodinase protein in OA-affected cartilage and allelic imbalance of OA risk polymorphism rs225014 at DIO2 in human OA joint tissues. *Ann Rheum Dis* 2012; **71**: 1254–1258.
33. Weiss HE, Roberts SJ, Schrooten J, *et al*. A semi-autonomous model of endochondral ossification for developmental tissue engineering. *Tissue Eng Part A* 2012; **18**: 1334–1343.
34. Guardiola O, Lafuste P, Brunelli S, *et al*. Cripto regulates skeletal muscle regeneration and modulates satellite cell determination by antagonizing myostatin. *Proc Natl Acad Sci U S A* 2012; **109**: E3231–E3240.
35. Iavarone F, Guardiola O, Scagliola A, *et al*. Cripto shapes macrophage plasticity and restricts EndMT in injured and diseased skeletal muscle. *EMBO Rep* 2020; **21**: e49075.
36. Gray PC, Shani G, Aung K, *et al*. Cripto binds transforming growth factor β (TGF- β) and inhibits TGF- β signaling. *Mol Cell Biol* 2006; **26**: 9268–9278.
37. Gray PC, Harrison CA, Vale W. Cripto forms a complex with activin and type II activin receptors and can block activin signaling. *Proc Natl Acad Sci U S A* 2003; **100**: 5193–5198.
38. David L, Mallet C, Mazerbourg S, *et al*. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. *Blood* 2007; **109**: 1953–1961.
39. Scharpfenecker M, van Dinther M, Liu Z, *et al*. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. *J Cell Sci* 2007; **120**(Pt 6): 964–972.
40. Goumans MJ, Valdimarsdottir G, Itoh S, *et al*. Balancing the activation state of the endothelium via two distinct TGF- β type I receptors. *EMBO J* 2002; **21**: 1743–1753.
41. Shore EM, Xu M, Feldman GJ, *et al*. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. *Nat Genet* 2006; **38**: 525–527.

42. Lee GH, Fujita M, Takaoka K, *et al.* A GPI processing phospholipase A2, PGAP6, modulates Nodal signaling in embryos by shedding CRIPTO. *J Cell Biol* 2016; **215**: 705–718.
 43. Watanabe K, Bianco C, Strizzi L, *et al.* Growth factor induction of Cripto-1 shedding by glycosylphosphatidylinositol-phospholipase D and enhancement of endothelial cell migration. *J Biol Chem* 2007; **282**: 31643–31655.
 44. Miharada K, Karlsson G, Rehn M, *et al.* Hematopoietic stem cells are regulated by Cripto, as an intermediary of HIF-1 α in the hypoxic bone marrow niche. *Ann N Y Acad Sci* 2012; **1266**: 55–62.
 45. Nakao A, Imamura T, Souchevnytskyi S, *et al.* TGF- β receptor-mediated signalling through Smad2, Smad3 and Smad4. *EMBO J* 1997; **16**: 5353–5362.
 46. Rosenzweig BL, Imamura T, Okadome T, *et al.* Cloning and characterization of a human type II receptor for bone morphogenetic proteins. *Proc Natl Acad Sci U S A* 1995; **92**: 7632–7636.
 47. Zhang J, Zhang X, Zhang L, *et al.* LRP8 mediates Wnt/ β -catenin signaling and controls osteoblast differentiation. *J Bone Miner Res* 2012; **27**: 2065–2074.
 48. Kemaladewi DU, de Gorter DJ, Aartsma-Rus A, *et al.* Cell-type specific regulation of myostatin signaling. *FASEB J* 2012; **26**: 1462–1472.
 49. Araki K, Imaizumi T, Okuyama K, *et al.* Efficiency of recombination by Cre transient expression in embryonic stem cells: comparison of various promoters. *J Biochem* 1997; **122**: 977–982.
- References 45–49 are cited only in the supplementary material.

SUPPLEMENTARY MATERIAL ONLINE

Supplementary materials and methods

Figure S1. Detailed histopathological evaluation (modified OARSI score) of medial and lateral tibiae and femora for ageing C57BL/6N and spontaneously OA-prone STR/ort mice

Figure S2. Cripto is expressed in the joints of mice subjected to medial meniscus destabilization (DMM)

Figure S3. Cripto is expressed in articular cartilage from severely affected donors with osteoarthritis

Figure S4. Cripto is expressed in ATDC5 cells at late time points of calcifying differentiation

Figure S5. Genetic deletion of *Tdgf1* (Cripto) prevents chondrocyte hypertrophy in E15.5 mouse metatarsals

Figure S6. Cripto genetic deletion effect on endogenous phospho-SMAD1 in E17.5 *Tdgf1^{tm2.2Mms}* metatarsals

Figure S7. Cripto genetic deletion effect on endogenous phospho-SMAD2 in E17.5 *Tdgf1^{tm2.2Mms}* metatarsals

Figure S8. Pharmacological inhibition of ALK1 prevents the enhancement in chondrogenic calcification induced by Cripto in C28/I2 cells

Table S1. Oligonucleotides used in this study for RT-qPCR (referred to in Supplementary materials and methods)

Table S2. Primary antibodies used in this study (referred to in Supplementary materials and methods)

Table S3. The short hairpin RNA (shRNA) constructs used in this study (referred to in Supplementary materials and methods)